ro-60-0175 has been researched along with Parkinson-Disease* in 1 studies
1 other study(ies) available for ro-60-0175 and Parkinson-Disease
Article | Year |
---|---|
The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.
Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD. Topics: Administration, Oral; Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electrophysiological Phenomena; Entopeduncular Nucleus; Ethylamines; Globus Pallidus; Indoles; Male; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT2 Receptor Agonists; Substantia Nigra | 2013 |